Transparency data

Clinical trials for medicines: authorisation assessment performance

Data on the time taken by MHRA to assess clinical trial applications and substantial amendments.

Document

Clinical trials data for medicines

Details

This data sets out the number of applications assessed by MHRA, split by phase and commercial and non-commercial sponsors.

The phase of application matches with the phases described in The Medicines (Products for Human Use) (Fees) Regulations and not the phase described in the application form.

Data is also provided for substantial amendments, split by phase. Monthly data is determined by the date initial assessment was completed, and not the receipt date.

Published 12 February 2015
Last updated 16 January 2018 + show all updates
  1. CTU metrics for December 2017 added to the page.
  2. Updated attachment for October and November
  3. CTU metrics for September added to the page.
  4. CTU metrics for August added to the page.
  5. CTU metrics up to July 2017 added to the page.
  6. CTU metrics updated for June 2017
  7. Clinical Trials metrics for May 2017 added to the page.
  8. Updated clinical trials data added for March
  9. Updated metrics for clinical trials
  10. updated metrics
  11. Added November updates for CTU metrics.
  12. Latest CTU metrics for October added.
  13. Updated metrics
  14. updated data
  15. Added July updates for CTU metrics.
  16. Added June updates for CTU metrics
  17. Added May updates for CTU metrics
  18. Additional data up to March 2016
  19. Updated: Clinical trials for medicines: authorisation assessment performance
  20. Clinical trials for medicines: authorisation assessment performance (April 2014 to March 2015)
  21. Clinical trials authorisation assessment performance has been updated.
  22. First published.